Factors associated with discontinuation of erectile dysfunction treatment

March 30, 2020

The factors associated with men ending treatment for erectile dysfunction have been reviewed in a study published in IJIR: Your Sexual Medicine Journal. The most influential factors reported were treatment ineffectiveness, side effects, the quality of one's intimate relationship and cost of treatment. The review also highlights the importance of men's beliefs with regards to erectile dysfunction and its treatment and suggests that these beliefs are potentially modifiable.

Erectile dysfunction, the persistent inability to develop or maintain a penile erection during sexual activity, is thought to affect up to 10% of men under 40 years and 70% of men over 70 years. Treatment includes medications delivered orally. Where these fail or are contraindicated, treatments are available which are administered via injection, or via suppositories. Finally, penile implants are available where all other treatments have failed.

The lead author; Mr Paul Williams said: "Erectile dysfunction can have a negative effect on men's quality of life. However, this can potentially be improved with successful treatment for the condition. The findings from our research indicate that rates of discontinuation for treatment are high. Understanding the reasons for discontinuation of treatment is essential with regards to improving treatment use and subsequently quality of life in this patient population".

Reviewing data on 14,371 men from 50 previous studies, researchers at City, University of London and East London NHS Foundation Trust, UK assessed the rates of discontinuation of erectile dysfunction treatment and the factors associated with it. Results indicated that discontinuation rates varied across treatments and that adherence to erectile dysfunction treatment is suboptimal.

The authors found that 12.1% of men taking oral medication, 15.2% of men taking injected medication and 31.5% of men taking suppositories reported inadequate or inconsistent erectile responses as their reason for discontinuing treatment. 2.5% of men taking oral medication, 8.1% of men injecting medication and 15% of men taking suppositories stated that they stopped treatment due to side effects including headaches, Peyronie's disease (a build-up of scar tissue in the penis) or urethral pain.

Regarding the quality of sexual relationships, the most commonly reported factors influencing whether men continued with erectile dysfunction treatment were loss of interest in a sexual relationship. This was reported by 6.6% of men taking oral medication, 8.8% of injecting medication, 8.9% of men taking suppositories and 6.9% of men with penile implants. 5.5% of men taking oral medication reported stopping treatment due their partner's perceived lack of interest in the sexual relationship, 5.5% of men described not being emotionally ready for sexual activity and 4.1% discontinued treatment because of conflict within their relationship. The findings appear to highlight the influence of the quality of a couple's sexual relationship on treatment use.

Mr. Paul Williams said: "Men's perceptions of their sexual relationships and their emotional readiness for sexual activity are important when considering the most appropriate treatment for a man and his partner."

The authors caution that due to an under-reporting of data on duration and severity of erectile dysfunction and relationship status in the majority of the included studies, the influence of these factors on treatment use could not be fully explored in this study. Further research should explore how beliefs affecting treatment adherence can be addressed during treatment to improve the quality of life of men and their partners, according to the authors.

The review also highlights the importance of men's beliefs with regards to erectile dysfunction and its treatment, with a potential effect on treatment continuation.

Mr Williams said: "Perceived ineffectiveness of treatment has a subjective element based on, for example, treatment expectations prior to treatment. We found that men who reported treatment side effects to a healthcare professional were more likely to continue with treatment. Exploring any misconceptions patients may have in relation to their treatment could potentially be beneficial to increasing treatment utilisation and therefore something that could help health care professionals when faced with treatment failure."

The authors suggest that future research would benefit from using psychological theory to explore barriers and enablers to treatment utilisation, as well as from measuring how treatment is utilised by patients. Taking such steps may lead to interventions aimed at improving treatment utilisation in this patient population, according to the authors.
-end-
Media Contact

Deborah Kendall
Assistant Press Officer
Springer Nature
T: +44 (0)20 7843 2653
E: deborah.kendall@springernature.com

Notes to editor:

1. Research article:

"Men's beliefs about treatment for erectile dysfunction--what influences treatment use? A systematic review"
IJIR: Your Sexual Medicine Journal 2020
DOI: 10.1038/s41443-020-0249-1

After the embargo lifts, the article will be available here:

https://www.nature.com/articles/s41443-020-0249-1

Please name the journal in any story you write. If you are writing for the web, please link to the article.

2. IJIR: Your Sexual Medicine Journal addresses sexual medicine for both genders as an interdisciplinary field. This includes basic science researchers, urologists, endocrinologists, cardiologists, family practitioners, gynecologists, internists, neurologists, psychiatrists, psychologists, radiologists and other health care clinicians.

Springer

Related Erectile Dysfunction Articles from Brightsurf:

European survey shows alarmingly low awareness of erectile dysfunction
Awareness of erectile dysfunction (ED) is alarmingly low in men and women aged 20 to 70, a new survey commissioned by the European Association of Urology (EAU) has revealed.

Erectile dysfunction drugs can help cells destroy misfolded proteins
PDE5 inhibitors -- which include the erectile dysfunction drugs sildenafil and tadalafil -- can activate the cell's protein quality-control systems and improve its ability to dispose of misfolded proteins.

Men with erectile dysfunction may face higher risk of death
Men with erectile dysfunction have a higher risk of death, regardless of their testosterone levels, suggests a study accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.

Factors associated with discontinuation of erectile dysfunction treatment
The factors associated with men ending treatment for erectile dysfunction have been reviewed in a study published in IJIR: Your Sexual Medicine Journal.

Concussions linked to erectile dysfunction in former NFL players
Former NFL players reporting concussion symptoms following head injury more likely to report erectile dysfunction and low testosterone levels.

Erectile dysfunction associated with lower work productivity in men
Erectile dysfunction (ED) was linked with loss of work productivity and with lower health-related quality of life in an International Journal of Clinical Practice study of more than 52,000 men from eight countries.

The global prevalence of erectile dysfunction
A review of published studies found that estimates for the global prevalence of erectile dysfunction vary widely, ranging from 3% to 76.5%.

Improved procedure for cancer-related erectile dysfunction
Melbourne surgeons have modified a minimally invasive technique to help men regain erectile function lost after prostate cancer surgery.

New discovery provides key to side effects caused by erectile dysfunction drugs
Study reveals several features of PDE6 that were previously unseen.

Convincing evidence that type 2 diabetes is a cause of erectile dysfunction
Evidence that type 2 diabetes is a cause of erectile dysfunction has been found in a large-scale genomic analysis.

Read More: Erectile Dysfunction News and Erectile Dysfunction Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.